An interventional study of Stop OsteoARthritis (SOAR) program and Living Well after ACLR program in Knee Injuries, Anterior Cruciate Ligament Rupture and Osteoarthritis, Knee, sponsored by University of British Columbia. Recruiting at 2 sites in Canada. Open to participants aged 16 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Anterior Cruciate Ligament Injuries with a site in Canada — 3 open to participants now, 6 under way, none of them phase 3. Anterior Cruciate Ligament Injuries · Canada.
Among the 18 studies in Anterior Cruciate Ligament Injuries with a site in Canada, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, and was the 16th registered.
627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.
Browse Anterior Cruciate Ligament Injuries studies →3 of the 18 studies in Anterior Cruciate Ligament Injuries with a site in Canada are open now. Recruiting first, the newest first:
McMaster University · Sites in Canada, Japan
Ages 10–18
Western University, Canada · Sites in Canada, United Kingdom
Ages 14–25
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.
This study: 16 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 56 across 460 interventional studies indexed under Anterior Cruciate Ligament Injuries.
Median enrollment 59 across the 16 interventional studies, 637 across the 2 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 4 studies filed under Anterior Cruciate Ligament Injuries — fewer than ten, so there is no comparison to draw.
2 of the studies in Anterior Cruciate Ligament Injuries with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06195423University of British ColumbiaStopping OsteoARthritis After an ACL Tear | 2026-12-30 |
| NCT06885372Western University, CanadaLong-term Follow up of the Stability 1 Trial | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Anterior Cruciate Ligament Injuries with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
By 2040, 25% of Canadians will have osteoarthritis, a disabling joint condition. Most people think osteoarthritis only affects older adults, but 50% of the 700,000 Canadian youth who hurt their knee playing sports annually will develop osteoarthritis by 40 years of age. These young people with old knees face knee pain and disability for much of their adult lives, interfering with parenting, work, and recreation. Yet, most do not know about osteoarthritis or how to reduce their risk.
In this clinical trial, people who have torn the Anterior Cruciate ligament in their knee and had reconstruction surgery 9-36 months previously will be randomized to receive either a 6-month virtual education and exercise therapy program called Stop OsteoARthritis (SOAR) or a minimal intervention control program. Researchers will test if those who received the SOAR program have larger gains in knee health, including pain, symptoms, function, and quality of life at 6, 12, and 24 months. Researchers will also use MRIs (baseline and 24 months) to assess how the SOAR program influences knee cartilage degeneration and its cost-effectiveness.
PURPOSE: Assess the effectiveness, efficiency, and implementation of a 6-month evidence-informed, digital (online), education and exercise-therapy program (SOAR - Stop OsteoARthritis) versus a minimal intervention control for people aged 16-35 years at risk of early-onset knee osteoarthritis (OA) due to a first time Anterior Cruciate Ligament Reconstruction (ACLR).
OBJECTIVES:
Primary Effectiveness Objective: Assess if self-reported knee pain, symptoms, function, and QoL (average of the Knee injury and OA Outcome Score pain, other symptoms, function in sport and recreation, and quality of life subscale scores; KOOS4) of people at risk of knee OA who receive SOAR is superior to those receiving a minimal intervention CONTROL at 6 (primary end-point), 12, and 24 months.
Primary Efficiency Objective: Assess the incremental cost-utility ratio of SOAR compared CONTROL (6, 12, 24 months)
Primary Implementation Objective: Assess provider adoption of the SOAR program.
Secondary Effectiveness Objectives:
Secondary Efficiency Objectives:
Secondary Implementation Objectives:
Exploratory Effectiveness Objectives: Explore the superiority of SOAR to CONTROL on the following outcomes (at 6, 12, and 24 months);
RESEARCH DESIGN:
The proposed trial is a two-arm, assessor-blinded, superiority, hybrid effectiveness-implementation type 1 randomized controlled trial with embedded cost-utility analyses and 1:1 interviews. This multi-focus design (effectiveness, implementation, efficacy) can accelerate research translation to real-world settings (Type 1: main focus-intervention effectiveness; secondary focus-understand implementation context). This design is appropriate as we have shown feasibility and indirect evidence of SOAR effect, the intervention is minimal risk, and there are no fully powered superiority trials to inform non-inferiority or equivalence designs.
The nature of the interventions do not allow for full blinding (physiotherapists cannot be blinded to treatment). We will employ proven methods from our proof-of-concept RCT to reduce allocation (online randomization module with schedule prepared by an arms-length statistician) and confirmation bias (outcome assessors and data analysts will be blinded to allocation).
STATISTICAL ANALYSES:
Primary analyses will be intent-to-treat (by randomization). Data missing more than 5% will be imputed using multiple imputations by chained equations to avoid bias. To ensure best practice, all outcome and demographic/prognostic variables will be included in imputation equations.
Demographics: Descriptive statistics will be calculated for demographic and potentially prognostic variables (time since injury and ACLR, concomitant injury, ACLR rehabilitation, graft type, reinjury, co-intervention, SES) and observed differences considered or controlled for when interpreting findings.
Effectiveness: SOAR superiority will be assessed with a generalized linear mixed regression model (GLMM) for the primary outcome (KOOS4 at 6 months) adjusted for baseline measure, time since ACLR, and sex. Adjusting for continuous time since ACLR versus stratifying improves power. Similar GLMMs will assess SOAR superiority for continuous secondary (PIH) and exploratory (knee extensor strength, adiposity, physical activity) outcomes at stated time points. Mixed effect logistic regression models (adjusted for the same variables as GLMMs) will assess SOAR superiority for binary secondary outcomes (MRI lesion worsening, achieving PASS) at stated time points. Analyses will yield valid results under the missing at random (MAR) assumption. The robustness of estimates to potential MAR assumption violations will be assessed with state-of-art methods.
Sex/Gender: To explore the effect of gender identity (women, man, gender-diverse) and sex (female, male, intersex) on outcome variables and intervention effect, all outcomes will be described by treatment group stratified by gender (KOOS4, Partner in Health Scale, cost-utility, physical activity, quality of life) or sex (MRI, knee extensor strength, adiposity) at all time points. We will estimate GLMMs and report intervention effect estimates stratified by sex (female, male) or gender (woman, man) as exploratory analyses to inform future studies. As 6% of our preliminary proof-of-concept randomized controlled trial participants identified gender diverse, descriptive statistics will also explore differences by cis and diverse gender.
Implementation: The % of physiotherapists achieving ≥85% on the fidelity checklist and checklist items with ≤70% fidelity will be reported. Provider and participants' responses to survey questions asking about barriers and facilitators of SOAR implementation will be summarized. Interview recordings related to identifying features of participant-provider interactions that facilitate self-management will be transcribed and de-identified. Data will be coded using a constant comparative approach, and categories will be developed by comparing and identifying meaningful patterns across codes. High-order themes will elucidate the relationship between categories. We will look for uniqueness by gender and, if found, reanalyze the data with a gender lens. Analysis trustworthiness and credibility will be fostered through data immersion, memoing, reflexive journaling, and team discussions. An audit of analytic decisions will be kept.
Efficiency outcome: Incremental cost-utility ratio will be estimated as (Cost_SOAR - Cost_CONTROL) ⁄(∆QALY_SOAR - ∆QALY_CONTROL) for the intervention and 6-month post-intervention period using nested imputation and nonparametric bootstrapping to model uncertainty around cost and QALY estimates. The contribution of each cost item to total healthcare resource use will be described by group, gender, and compliance (full, partial).
627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.
This study's planned enrollment of 210 is above the median of 56 across 460 interventional studies indexed under Anterior Cruciate Ligament Injuries.
Browse Anterior Cruciate Ligament Injuries studies →University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Compared within Anterior Cruciate Ligament Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Knee Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a first-time ACL tear followed by reconstruction surgery randomized to the SOAR program group will complete a 6-month SOAR program (one-time Knee Camp, weekly home-based exercise therapy and physical activity with tracking, weekly 1:1 physiotherapist counseling sessions, and optional weekly group-based exercise classes) Consented trained physiotherapists will deliver the SOAR program throughout the study period to one or more SOAR program participants. Physiotherapists and SOAR participants will be randomly paired.
Behavioral: Stop OsteoARthritis (SOAR) program
Participants with a first-time ACL tear followed by reconstruction surgery randomized to the minimal control (Living Well after ACLR) group will complete a 6-month minimal intervention control program (educational video, workbook, activity tracking, and one 1:1 physiotherapist counseling session).
Behavioral: Living Well after ACLR program
The SOAR program is a 6-month, online-delivered (videoconferencing), PT-guided knee health program which consists of; 1. Knee Camp: Includes interactive education, and 1:1 physiotherapy knee exam and counseling session to co-identify home-based exercise-therapy and physical activity goals to address participants' unique functional limitations. Participants are given a wrist-worn activity monitor to wear 24hours/day. 2. Individualized Weekly Home-based Exercise-Therapy and Physical Activity Program: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises and physical activity are tracked with an online form and the activity monitor. Participants can also attend an optional weekly group class. 3. Weekly PT-guided Exercise-Therapy and Physical Activity Counselling: Each week, participants attend a 1:1 physiotherapist counseling session to modify exercise-therapy and physical activity goals.
Also known as: SOAR
Participants in the minimal intervention CONTROL group will receive access to a 30-minute educational video (knee anatomy, ACLR information, general exercise, physical activity, and goal-setting principles), a best practice workbook, one video-recorded virtual session with a physiotherapist (naïve to SOAR) who will explain the booklet and answer questions but not volunteer information beyond the video or booklet and the same wrist-worn activity tracker as the experimental group.
Also known as: CONTROL
Self-reported knee-related pain, symptoms, function in sport and quality of life over 6 months (effectiveness outcome) (ACL tear participants)
Patient partners identify pain, function and quality of life, which can be impaired up to 10-years post-ACLR, as priority outcomes. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a valid and reliable patient-reported outcome measure (PROM) with sub-scales for knee pain (9-items), other symptoms (7-items), function in daily living (ADL; 17-items), function in sport/recreation (5-items), and quality of life (4-items) across injury and OA populations. Each subscale item is scored on a 5-point scale and individual subscale items summed and transformed to a 0-100 scale with higher scores indicating better outcome. The KOOS4 which is an average of 4 sub-scales (excluding ADL) is a recommended and accepted primary outcome for ACLR RCTs and was responsive in our proof of concept RCT.
Time frame: Change from baseline KOOS score at 6 months (ACL tear participants)
Incremental cost-utility ratio over 6 months (efficiency outcome)
To assess SOARs value for money (health systems perspective) we will estimate the incremental cost/mean change in Quality-Adjusted Life Years (QALY) gained by SOAR versus CONTROL at 6 months. Costs will be estimated with the Health Resource Utilization questionnaire (HRU) as the study population often uses resources not captured in administrative data and evidence of good agreement between administrative and prospectively collected HRU data. The HRU captures provider visits, hospital admissions, lab and diagnostic tests and medication use. QALYs will be estimated from health-related quality of life (EQ-5D-5L) using area under the curve analysis. The EQ-5D-5L is widely used for cost-utility analyses in OA, and assesses 5 levels across 5 health domains to produce a health state profile using Canadian conversion tariffs.
Time frame: Incremental cost-utility ratio at 6 months
Provider adoption of SOAR over 6 months (implementation outcome) (physiotherapist participants)
A 40-item fidelity checklist, refined in our proof-of-concept RCT, will be applied to all video-recorded 1:1 counseling sessions for 4 participants per PT, and the median % fidelity for each PT and checklist item reported. Items reaching ≤70% will be identified and inform the development of PT training modules to facilitate future evaluation and implementation.
Time frame: Percent fidelity at 6 months (physiotherapist participants)
Patient Acceptable Symptom State over 6 months (ACL tear participants)
To help interpret the clinical relevance of the KOOS4, the percentage of participants in both study groups to reach KOOS4 and KOOS sub-scale Patient Acceptable Symptom State (PASS) scores (KOOS4 79; pain 89; symptoms 83; ADL 95, sport 72; QoL 73) will be reported.
Time frame: Change from baseline patient acceptable symptom state score at 6 months (ACL tear participants)
Self-reported perceived self-management over 6 months (ACL tear participants)
The 12 item Partner in Health Scale will be used to measure perceived self-management (active involvement to self-manage a chronic condition). Each item is scored on a 0-9 point Likert scale. Scores on individual items are summed to produce a total score ranging between 0 and 96, with 0 representing no perceived self-management and 96 representing full perceived self-management. The total time for this questionnaire is 3 minutes. The Partner in Health Scale is valid and reliable across numerous chronic conditions.
Time frame: Change from baseline self-reported perceived self-management at 6 months (ACL tear participants)
Osteoarthritis MRI features over 24 months (ACL tear participants)
MRI features of OA (cartilage defect, bone marrow lesions) are important for early disease staging and common after ACLR. The impact of exercise on these outcomes post-ACLR is unknown. The valid semi-quantitative MRI OA knee score (MOAKS) will be applied to 3D proton-density (PD) gradient MRI sequences (3T scanner, Philips Elition, 8-channel knee coil). Positioning aids will immobilize the knee to ensure consistent scans. Radiology fellows will conduct MOAKS ratings blinded to group allocation. OA feature worsening will be defined as an increase in the size of the lesion using established methods.
Time frame: Change from baseline MRI at 24 months (ACL tear participants)
Health resource use costs over 24 months
Monthly health resource use costs (HRU) will be reported over the 24-month study period.
Time frame: Health resource use costs over 24 months
Intervention delivery costs over 6 months
The cost to deliver the SOAR and CONTROL (Living Well with ACLR) interventions will be tracked and reported.
Time frame: Intervention delivery costs over 6 months
Participant perceived barriers and facilitators of program delivery over 6 months (ACL tear participants)
On completion of the intervention, participants will receive a follow-up survey which will include questions to capture information about their perceived barriers and facilitators of program delivery, and therapeutic alliance with their PT (Consultation and Relational Empathy measure (CARE)).
Time frame: Follow-up surveys will take place at 6 months (ACL tear participants)
Provider perceived barriers and facilitators of program delivery over 6 months (physiotherapist participants)
After PT's are done delivering the SOAR program they will receive a follow-up survey including questions to capture information about their perceived barriers and facilitators of SOAR program delivery, SOAR and BAP training, confidence in BAP, SMART goal setting, shared decision making, virtual PT delivery, and perceived impacts on patient and clinic flow.
Time frame: Follow-up surveys will take place at 6 months (physiotherapist participants)
Features of PT counselling that promote self-management over 6 months (ACL tear participants)
Semi-structured 1:1 interviews will be conducted with a purposive maximum variation sample (gender, age, adherence, time since injury) of 15-20 participants. Using video-cued narrative reflection, participants will self-select meaningful exchanges with their PT that promoted self-management while viewing a Knee Camp recording and a random weekly counselling session. Participants will be able to pause and rewind the recording to identify, and elaborate on significant moments. A definition of self-management and context-specific examples will be provided. Probe and prompts will provide elaboration. Field notes will be taken, and interviews recorded. Ongoing analyses will inform sampling, and data collection will cease when no new themes are identified. Video-recorded healthcare interactions are acceptable and provide valuable practice insights. Video-cued interviews yield rich data as participants simultaneously identify, engage and reflect on their lived experience.
Time frame: 1:1 interviews will be conducted at 6 months (ACL tear participants)
Self-reported knee-related pain, symptoms, function in sport and quality of life over 12 months (ACL tear participants)
Patient partners identify pain, function and quality of life, which can be impaired up to 10-years post-ACLR, as priority outcomes. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a valid and reliable patient-reported outcome measure (PROM) with sub-scales for knee pain (9-items), other symptoms (7-items), function in daily living (ADL; 17-items), function in sport/recreation (5-items), and quality of life (4-items) across injury and OA populations. Each subscale item is scored on a 5-point scale and individual subscale items summed and transformed to a 0-100 scale with higher scores indicating better outcome. The KOOS4 which is an average of 4 sub-scales (excluding ADL) is a recommended and accepted primary outcome for ACLR RCTs and was responsive in our proof of concept RCT.
Time frame: Change from baseline KOOS score at 12 months (ACL tear participants)
Self-reported knee-related pain, symptoms, function in sport and quality of life over 24 months (ACL tear participants)
Patient partners identify pain, function and quality of life, which can be impaired up to 10-years post-ACLR, as priority outcomes. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a valid and reliable patient-reported outcome measure (PROM) with sub-scales for knee pain (9-items), other symptoms (7-items), function in daily living (ADL; 17-items), function in sport/recreation (5-items), and quality of life (4-items) across injury and OA populations. Each subscale item is scored on a 5-point scale and individual subscale items summed and transformed to a 0-100 scale with higher scores indicating better outcome. The KOOS4 which is an average of 4 sub-scales (excluding ADL) is a recommended and accepted primary outcome for ACLR RCTs and was responsive in our proof of concept RCT.
Time frame: Change from baseline KOOS score at 24 months (ACL tear participants)
Incremental cost-utility ratio over 12 months
To assess SOARs value for money (health systems perspective) we will estimate the incremental cost/mean change in Quality-Adjusted Life Years (QALY) gained by SOAR versus CONTROL at 12 months. Costs will be estimated with the Health Resource Utilization questionnaire (HRU) as the study population often uses resources not captured in administrative data and evidence of good agreement between administrative and prospectively collected HRU data. The HRU captures provider visits, hospital admissions, lab and diagnostic tests and medication use. QALYs will be estimated from health-related quality of life (EQ-5D-5L) using area under the curve analysis. The EQ-5D-5L is widely used for cost-utility analyses in OA, and assesses 5 levels across 5 health domains to produce a health state profile using Canadian conversion tariffs.
Time frame: Incremental cost-utility ratio at 12 months
Incremental cost-utility ratio over 24 months
To assess SOARs value for money (health systems perspective) we will estimate the incremental cost/mean change in Quality-Adjusted Life Years (QALY) gained by SOAR versus CONTROL at 24 months. Costs will be estimated with the Health Resource Utilization questionnaire (HRU) as the study population often uses resources not captured in administrative data and evidence of good agreement between administrative and prospectively collected HRU data. The HRU captures provider visits, hospital admissions, lab and diagnostic tests and medication use. QALYs will be estimated from health-related quality of life (EQ-5D-5L) using area under the curve analysis. The EQ-5D-5L is widely used for cost-utility analyses in OA, and assesses 5 levels across 5 health domains to produce a health state profile using Canadian conversion tariffs.
Time frame: Incremental cost-utility ratio at 24 months
Patient Acceptable Symptom State over 12 months (ACL tear participants)
To help interpret the clinical relevance of the KOOS4, the percentage of participants in both study groups to reach KOOS4 and KOOS sub-scale Patient Acceptable Symptom State (PASS) scores (KOOS4 79; pain 89; symptoms 83; ADL 95, sport 72; QoL 73) will be reported.
Time frame: Change from baseline Patient Acceptable Symptom State score at 12 months (ACL tear participants)
Patient Acceptable Symptom State over 24 months (ACL tear participants)
To help interpret the clinical relevance of the KOOS4, the percentage of participants in both study groups to reach KOOS4 and KOOS sub-scale Patient Acceptable Symptom State (PASS) scores (KOOS4 79; pain 89; symptoms 83; ADL 95, sport 72; QoL 73) will be reported.
Time frame: Change from baseline Patient Acceptable Symptom State score at 24 months (ACL tear participants)
Self-reported perceived self-management over 12 months (ACL tear participants)
The 12 item Partner in Health Scale will be used to measure perceived self-management (active involvement to self-manage a chronic condition). Each item is scored on a 0-9 point Likert scale. Scores on individual items are summed to produce a total score ranging between 0 and 96, with 0 representing no perceived self-management and 96 representing full perceived self-management. The total time for this questionnaire is 3 minutes. The Partner in Health Scale is valid and reliable across numerous chronic conditions.
Time frame: Change from baseline self-reported perceived self-management at 12 months (ACL tear participants)
Perceived self-management over 24 months (ACL tear participants)
The 12 item Partner in Health Scale will be used to measure perceived self-management (active involvement to self-manage a chronic condition). Each item is scored on a 0-9 point Likert scale. Scores on individual items are summed to produce a total score ranging between 0 and 96, with 0 representing no perceived self-management and 96 representing full perceived self-management. The total time for this questionnaire is 3 minutes. The Partner in Health Scale is valid and reliable across numerous chronic conditions.
Time frame: Change from baseline self-reported perceived self-management at 24 months (ACL tear participants)
Self-reported function over 6 months (ACL tear participants)
The 3 item Patient Specific Functional Scale will be used to identify, quantify and assess changes in functional limitations that are most relevant to participants. This scale prompts participants to identify three activities important to them and rate their ability to perform each activity on a 10-point numerical rating scale. Individual scale scores are summed and transformed to a 0-100 scale with higher scores indicating better outcomes. The total time for this questionnaire is 3 minutes. The Patient-Specific Functional Scale is valid and reliable for use in persons with a knee injury.
Time frame: Change from baseline self-reported function at 6 months (ACL tear participants)
Self-reported function over 12 months (ACL tear participants)
The 3 item Patient Specific Functional Scale will be used to identify, quantify and assess changes in functional limitations that are most relevant to participants. This scale prompts participants to identify three activities important to them and rate their ability to perform each activity on a 10-point numerical rating scale. Individual scale scores are summed and transformed to a 0-100 scale with higher scores indicating better outcomes. The total time for this questionnaire is 3 minutes. The Patient-Specific Functional Scale is valid and reliable for use in persons with a knee injury.
Time frame: Change from baseline self-reported function at 12 months (ACL tear participants)
Self-reported function over 24 months (ACL tear participants)
The 3 item Patient Specific Functional Scale will be used to identify, quantify and assess changes in functional limitations that are most relevant to participants. This scale prompts participants to identify three activities important to them and rate their ability to perform each activity on a 10-point numerical rating scale. Individual scale scores are summed and transformed to a 0-100 scale with higher scores indicating better outcomes. The total time for this questionnaire is 3 minutes. The Patient-Specific Functional Scale is valid and reliable for use in persons with a knee injury.
Time frame: Change from baseline self-reported function at 24 months (ACL tear participants)
Self-reported knee-specific self-efficacy over 6 months (ACL tear participants)
Self-efficacy, or one's belief in their own ability to organize and execute the actions required to manage a prospective situation, can predict health behaviours including exercise participation. The KSES is a valid and reliable measure of knee-specific self-efficacy in people with a sport-related knee injury in the previous 5-years. The KSES consists of 22 items organized into 2 sub-scales (present and future self-efficacy). Each item is scored on an 0-10-point Likert scale, with 0 indicating no confidence and 10 indicating full confidence. Individual item scores are summed to produce a total score. Higher scores indicate higher levels of self-efficacy.
Time frame: Change from baseline self-reported knee-specific self-efficacy at 6 months (ACL tear participants)
Self-reported knee-specific self-efficacy over 12 months (ACL tear participants)
Self-efficacy, or one's belief in their own ability to organize and execute the actions required to manage a prospective situation, can predict health behaviours including exercise participation. The KSES is a valid and reliable measure of knee-specific self-efficacy in people with a sport-related knee injury in the previous 5-years. The KSES consists of 22 items organized into 2 sub-scales (present and future self-efficacy). Each item is scored on an 0-10-point Likert scale, with 0 indicating no confidence and 10 indicating full confidence. Individual item scores are summed to produce a total score. Higher scores indicate higher levels of self-efficacy.
Time frame: Change from baseline self-reported knee-specific self-efficacy at 12 months (ACL tear participants)
Self-reported knee-specific self-efficacy over 24 months (ACL tear participants)
Self-efficacy, or one's belief in their own ability to organize and execute the actions required to manage a prospective situation, can predict health behaviours including exercise participation. The KSES is a valid and reliable measure of knee-specific self-efficacy in people with a sport-related knee injury in the previous 5-years. The KSES consists of 22 items organized into 2 sub-scales (present and future self-efficacy). Each item is scored on an 0-10-point Likert scale, with 0 indicating no confidence and 10 indicating full confidence. Individual item scores are summed to produce a total score. Higher scores indicate higher levels of self-efficacy.
Time frame: Change from baseline self-reported knee-specific self-efficacy at 24 months (ACL tear participants)
Self-reported fear of movement and re-injury over 6 months (ACL tear participants)
The 11 item Tampa Scale of Kinesiophobia will be used to measure self-reported fear of movement and re-injury. Each item is scored on a 0-4 point Likert-scale, with 0 indicating no fear of movement and 4 indicating greater fear of movement. The item scores are summed to produce a total score ranging between 0 and 44, with higher values indicating a higher degree of fear of movement. The total time for this questionnaire is 3 minutes. The Tampa Scale of Kinesiophobia has evidence of known-group validity (scores discriminated between athletes who returned and did not return to pre-injury sports participation level after knee trauma).
Time frame: Change from baseline self-reported fear of movement and re-injury at 6 months (ACL tear participants)
Self-reported fear of movement and re-injury over 12 months (ACL tear participants)
The 11 item Tampa Scale of Kinesiophobia will be used to measure self-reported fear of movement and re-injury. Each item is scored on a 0-4 point Likert-scale, with 0 indicating no fear of movement and 4 indicating greater fear of movement. The item scores are summed to produce a total score ranging between 0 and 44, with higher values indicating a higher degree of fear of movement. The total time for this questionnaire is 3 minutes. The Tampa Scale of Kinesiophobia has evidence of known-group validity (scores discriminated between athletes who returned and did not return to pre-injury sports participation level after knee trauma).
Time frame: Change from baseline self-reported fear of movement and re-injury at 12 months (ACL tear participants)
Self-reported fear of movement and re-injury over 24 months (ACL tear participants)
The 11 item Tampa Scale of Kinesiophobia will be used to measure self-reported fear of movement and re-injury. Each item is scored on a 0-4 point Likert-scale, with 0 indicating no fear of movement and 4 indicating greater fear of movement. The item scores are summed to produce a total score ranging between 0 and 44, with higher values indicating a higher degree of fear of movement. The total time for this questionnaire is 3 minutes. The Tampa Scale of Kinesiophobia has evidence of known-group validity (scores discriminated between athletes who returned and did not return to pre-injury sports participation level after knee trauma).
Time frame: Change from baseline self-reported fear of movement and re-injury at 24 months (ACL tear participants)
Change in Knee Extension Power over 6 months (ACL tear participants)
A computerized dynamometer (Biodex®) will be used to assess and calculate knee extension power (Watts). After completing the protocol for normalized peak concentric knee extension and flexion torque the participants' knee joint will be fixed in 60 degrees of sagittal plane flexion. After three practice trials and a 30-second rest, participants will be instructed to straighten their knee as hard and as fast as they can for five seconds. This will be repeated five times with a 30-second rest period between each repetition. The total time for this test is 10 minutes. Computerized dynamometry (Biodex®) is a reliable, valid, relevant, and recommended measure of muscle power.
Time frame: Change from baseline knee extensor muscle power at 6 months (ACL tear participants)
Change in Knee Extension Power over 12 months (ACL tear participants)
A computerized dynamometer (Biodex®) will be used to assess and calculate knee extension power (Watts). After completing the protocol for normalized peak concentric knee extension and flexion torque the participants' knee joint will be fixed in 60 degrees of sagittal plane flexion. After three practice trials and a 30-second rest, participants will be instructed to straighten their knee as hard and as fast as they can for five seconds. This will be repeated five times with a 30-second rest period between each repetition. The total time for this test is 10 minutes. Computerized dynamometry (Biodex®) is a reliable, valid, relevant, and recommended measure of muscle power.
Time frame: Change from baseline knee extensor muscle power at 12 months (ACL tear participants)
Change in Knee Extension Power over 24 months (ACL tear participants)
A computerized dynamometer (Biodex®) will be used to assess and calculate knee extension power (Watts). After completing the protocol for normalized peak concentric knee extension and flexion torque the participants' knee joint will be fixed in 60 degrees of sagittal plane flexion. After three practice trials and a 30-second rest, participants will be instructed to straighten their knee as hard and as fast as they can for five seconds. This will be repeated five times with a 30-second rest period between each repetition. The total time for this test is 10 minutes. Computerized dynamometry (Biodex®) is a reliable, valid, relevant, and recommended measure of muscle power.
Time frame: Change from baseline knee extensor muscle power at 24 months (ACL tear participants)
Change in Knee Flexion Power over 6 months (ACL tear participants)
A computerized dynamometer (Biodex®) will be used to assess and calculate knee flexion power (Watts). After completing the protocol for normalized peak concentric knee extension and flexion torque the participants' knee joint will be fixed in 60 degrees of sagittal plane flexion. After three practice trials and a 30-second rest, participants will be instructed to bend their knee as hard and as fast as they can for five seconds. This will be repeated five times with a 30-second rest period between each repetition. The total time for this test is 10 minutes. Computerized dynamometry (Biodex®) is a reliable, valid, relevant, and recommended measure of muscle power.
Time frame: Change from baseline knee extensor muscle power at 6 months (ACL tear participants)
Change in Knee Flexion Power over 12 months (ACL tear participants)
A computerized dynamometer (Biodex®) will be used to assess and calculate knee flexion power (Watts). After completing the protocol for normalized peak concentric knee extension and flexion torque the participants' knee joint will be fixed in 60 degrees of sagittal plane flexion. After three practice trials and a 30-second rest, participants will be instructed to bend their knee as hard and as fast as they can for five seconds. This will be repeated five times with a 30-second rest period between each repetition. The total time for this test is 10 minutes. Computerized dynamometry (Biodex®) is a reliable, valid, relevant, and recommended measure of muscle power.
Time frame: Change from baseline knee extensor muscle power at 12 months (ACL tear participants)
Change in Knee Flexion Power over 24 months (ACL tear participants)
A computerized dynamometer (Biodex®) will be used to assess and calculate knee flexion power (Watts). After completing the protocol for normalized peak concentric knee extension and flexion torque the participants' knee joint will be fixed in 60 degrees of sagittal plane flexion. After three practice trials and a 30-second rest, participants will be instructed to bend their knee as hard and as fast as they can for five seconds. This will be repeated five times with a 30-second rest period between each repetition. The total time for this test is 10 minutes. Computerized dynamometry (Biodex®) is a reliable, valid, relevant, and recommended measure of muscle power.
Time frame: Change from baseline knee extensor muscle power at 24 months (ACL tear participants)
Change in Daily Average Moderate to Vigorous Physical Activity over 6 months (ACL tear participants)
A small, lightweight hip worn wearable triaxial accelerometer (ActiGraph GT3X®) will be used to assess physical activity. Participants will be asked to wear this device (attached via an elastic belt around their waist), for a period of 7 consecutive days removing only for bathing/swimming activities. The average number of 10-minute moderate-to-vigorous physical activity bouts over the 7-day period will be calculated. Accelerometry is a valid measure of physical activity in youth and young adult populations.
Time frame: Change from baseline daily average moderate to vigorous physical activity at 6 months (ACL tear participants)
Change in Daily Average Moderate to Vigorous Physical Activity over 12 months (ACL tear participants)
A small, lightweight hip worn wearable triaxial accelerometer (ActiGraph GT3X®) will be used to assess physical activity. Participants will be asked to wear this device (attached via an elastic belt around their waist), for a period of 7 consecutive days removing only for bathing/swimming activities. The average number of 10-minute moderate-to-vigorous physical activity bouts over the 7-day period will be calculated. Accelerometry is a valid measure of physical activity in youth and young adult populations.
Time frame: Change from baseline daily average moderate to vigorous physical activity at 12 months (ACL tear participants)
Change in Daily Average Moderate to Vigorous Physical Activity over 24 months (ACL tear participants)
A small, lightweight hip worn wearable triaxial accelerometer (ActiGraph GT3X®) will be used to assess physical activity. Participants will be asked to wear this device (attached via an elastic belt around their waist), for a period of 7 consecutive days removing only for bathing/swimming activities. The average number of 10-minute moderate-to-vigorous physical activity bouts over the 7-day period will be calculated. Accelerometry is a valid measure of physical activity in youth and young adult populations.
Time frame: Change from baseline daily average moderate to vigorous physical activity at 24 months (ACL tear participants)
Change in Self-Reported Physical Activity over 6 months (ACL tear participants)
The 4 item Godin Leisure Time Questionnaire will be used to measure self-reported physical activity. Using the number of 15-minute bouts of mild, moderate, and strenuous physical activity a participant engages in over a typical seven-day period weekly metabolic equivalents of physical activity are calculated. The total time for this questionnaire is 1 minute. The Godin Leisure Time Questionnaire has been validated to assess physical activity.
Time frame: Change from baseline self-reported physical activity at 6 months (ACL tear participants)
Change in Self-Reported Physical Activity over 12 months (ACL tear participants)
The 4 item Godin Leisure Time Questionnaire will be used to measure self-reported physical activity. Using the number of 15-minute bouts of mild, moderate, and strenuous physical activity a participant engages in over a typical seven-day period weekly metabolic equivalents of physical activity are calculated. The total time for this questionnaire is 1 minute. The Godin Leisure Time Questionnaire has been validated to assess physical activity.
Time frame: Change from baseline self-reported physical activity at 12 months (ACL tear participants)
Change in Self-Reported Physical Activity over 24 months (ACL tear participants)
The 4 item Godin Leisure Time Questionnaire will be used to measure self-reported physical activity. Using the number of 15-minute bouts of mild, moderate, and strenuous physical activity a participant engages in over a typical seven-day period weekly metabolic equivalents of physical activity are calculated. The total time for this questionnaire is 1 minute. The Godin Leisure Time Questionnaire has been validated to assess physical activity.
Time frame: Change from baseline self-reported physical activity at 24 months (ACL tear participants)
Change in Health-Related Quality of Life over 6 months (ACL tear participants)
The EQ-5D-5L is a simple, reliable self-report instrument designed to assess generic health for clinical and economic appraisal across multiple countries and conditions (see attachment 16-EQ-5D-5L). The EQ-5D-5L provides information about 5 levels of problems across 5 health domains (anxiety/depression, pain/discomfort, mobility, self-care, usual activities), and a 0-to-100 visual analogue scale rating for self-related health (EQ-5D-5Lindex). EQ-5D-5Lindex values will be reported at each time point.
Time frame: Change from baseline health-related quality of life at 6 months (ACL tear participants)
Change in Health-Related Quality of Life over 12 months (ACL tear participants)
The EQ-5D-5L is a simple, reliable self-report instrument designed to assess generic health for clinical and economic appraisal across multiple countries and conditions (see attachment 16-EQ-5D-5L). The EQ-5D-5L provides information about 5 levels of problems across 5 health domains (anxiety/depression, pain/discomfort, mobility, self-care, usual activities), and a 0-to-100 visual analogue scale rating for self-related health (EQ-5D-5Lindex). EQ-5D-5Lindex values will be reported at each time point.
Time frame: Change from baseline health-related quality of life at 12 months (ACL tear participants)
Change in Health-Related Quality of Life over 24 months (ACL tear participants)
The EQ-5D-5L is a simple, reliable self-report instrument designed to assess generic health for clinical and economic appraisal across multiple countries and conditions (see attachment 16-EQ-5D-5L). The EQ-5D-5L provides information about 5 levels of problems across 5 health domains (anxiety/depression, pain/discomfort, mobility, self-care, usual activities), and a 0-to-100 visual analogue scale rating for self-related health (EQ-5D-5Lindex). EQ-5D-5Lindex values will be reported at each time point.
Time frame: Change from baseline health-related quality of life at 24 months (ACL tear participants)
Change in Fat Mass Index over 6 months (ACL tear participants)
Fat mass index (kg/m2) will be measured with Bioelectrical Impedance (Tanita Body Composition Analyzer, Model TBF-300A, Tanita Inc., USA). Participants will stand barefoot on the bioelectrical impedance platform during which the resistance to the flow of this single, high frequency alternating electrical current (500 A at 50 kHz) will be measured. Bioelectrical Impedance is a feasible method for assessing and tracking body composition in clinical settings and has been shown to be valid and reliable in child, youth, and adult populations. This test will take 5 minutes to complete. The device will be calibrated prior to each scan (according to the manufacturer's protocol).
Time frame: Change from baseline fat mass index at 6 months (ACL tear participants)
Change in Fat Mass Index over 12 months (ACL tear participants)
Fat mass index (kg/m2) will be measured with Bioelectrical Impedance (Tanita Body Composition Analyzer, Model TBF-300A, Tanita Inc., USA). Participants will stand barefoot on the bioelectrical impedance platform during which the resistance to the flow of this single, high frequency alternating electrical current (500 A at 50 kHz) will be measured. Bioelectrical Impedance is a feasible method for assessing and tracking body composition in clinical settings and has been shown to be valid and reliable in child, youth, and adult populations. This test will take 5 minutes to complete. The device will be calibrated prior to each scan (according to the manufacturer's protocol).
Time frame: Change from baseline fat mass index at 12 months (ACL tear participants)
Change in Fat Mass Index over 24 months (ACL tear participants)
Fat mass index (kg/m2) will be measured with Bioelectrical Impedance (Tanita Body Composition Analyzer, Model TBF-300A, Tanita Inc., USA). Participants will stand barefoot on the bioelectrical impedance platform during which the resistance to the flow of this single, high frequency alternating electrical current (500 A at 50 kHz) will be measured. Bioelectrical Impedance is a feasible method for assessing and tracking body composition in clinical settings and has been shown to be valid and reliable in child, youth, and adult populations. This test will take 5 minutes to complete. The device will be calibrated prior to each scan (according to the manufacturer's protocol).
Time frame: Change from baseline fat mass index at 24 months (ACL tear participants)
Change in Knee Cartilage Health over 24 months (ACL tear participants)
Preliminary research links exercise-therapy to better knee cartilage health in people at risk of post-traumatic OA (post-meniscectomy) and early atraumatic OA up to 12-months. We will provide further insight over 24-months by quantifying changes in cartilage T2 relaxation times (sagittal multi-echo-spin-echo pulse sequences;12 echos) which are widely used as a marker of early degeneration. An senior imaging scientist will segment the cartilage manually and calculate average T2 for femoral, tibial and patellar cartilage plates.
Time frame: Change from baseline knee cartilage health at 24 months (ACL tear participants)
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 279 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's planned 31 months is close to that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 14 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anterior Cruciate Ligament Injuries →
University of British Columbia →